Methods for diagnosing benign prostatic hyperplasia
US5698402A · kind A · utility
20Cited by
1References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 23, 1995 |
| Grant date | Dec 16, 1997 |
| Priority date | — |
| Expiry date | Feb 23, 2015 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/57434
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to a method for diagnosing benign prostatic hyperplasia (BPH) in a male human patient without requiring a biopsy. The total prostate specific antigen (PSA) level in the blood or serum of the patient is measured. If the patient has a total PSA level of between 2.5 ng/ml, (4.0 ng/ml for those 60 years or over), and 10.0 ng/ml, then the free PSA level in the blood or serum of the patient is measured. The proportion of free PSA to total PSA is calculated. If this proportion is equal to or greater than about 25%, then the patient is diagnosed as having BPH.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.